科興製藥(688136.SH)：與東南大學簽署共建細胞外囊泡遞藥技術產業化聯合創新實驗室的合作協議書
格隆匯9月26日丨科興製藥(688136.SH)公佈，公司全資子公司深圳科興藥業有限公司(“深圳科興藥業”)於2021年9月26日與東南大學簽署《關於共建細胞外囊泡遞藥技術產業化聯合創新實驗室的合作協議書》，雙方擬聯合共建“東南大學—科興製藥細胞外囊泡遞藥技術產業化聯合創新實驗室”(“聯創實驗室”)，在細胞外囊泡遞藥技術產業化的研究開發、產學研聯合、高新技術成果轉化、人才培養等方面開展全方位、多層次的合作。
合作期限：第一期合作期限為3年，根據第一期合作情況並徵得合作雙方同意，可以續簽。
合作內容：聯創實驗室的建設重點與合作科研方向將圍繞粒徑在200nm以下的細胞外囊泡載藥的研究、開發與產業化及相關平台的建設開展。
經費：深圳科興藥業列支專項預算，為聯創實驗室的建設和運行提供研發經費支持。為支持該聯創實驗室的研發工作，深圳科興藥業分三年累計提供研發經費總投入人民幣1000萬元。
知識產權及收益分配：在合作期間、合作範圍內產生的知識產權雙方共同所有；知識產權雙方享有共同署名權；就上述知識產權，一方可直接或經自行轉化實施後，獨自向第三方進行許可或授權使用，就此產生的收益歸本方所有，不再向另一方進行收益分配。
外泌體是一種直徑為30-150nm的細胞外囊泡，具有獨特的介導細胞間通信作用。據目前研究成果，外泌體可有效遞送核酸、蛋白質、小分子等多種藥物分子，實現高靶向性，達到較好的療效。
此次合作將推動國內外泌體載藥技術向產業化的發展，聯創實驗室將獲得穩定可靠的商業化規模的生產工藝和質量控制方法，並開發外泌體載藥-遞送-釋放技術。公司基於此技術平台，可應用於核酸藥物的研發及開發其他新型藥物，進一步豐富公司的產品管線，提升在研產品的技術含量和創新性。
通過此次合作，有助於公司在尖端技術、高新技術、關鍵技術領域打破壁壘並取得突破，為公司新藥研發打下堅實基礎，促進公司在有重大前景的新興生物技術領域的佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
